PURPOSE: The runt-related transcription factor, Runx2 may have an oncogenic role in mediating metastatic events in breast cancer, but whether Runx2 has a role in the early phases of breast cancer development is not clear. We examined the expression of Runx2 and its relationship with oestrogen receptor (ER) and progesterone receptor (PR) in breast cancer cell lines and tissues. METHODS: Two human breast cancer cell lines, MCF-7 and MDA-MB-231 were transiently transfected with vectors expressing either Runx2 or ER and the levels of both proteins and mRNA were examined by Western blot analysis and quantitative real-time PCR, respectively. Runx2 expression was also examined in tissue microarray sections of 123 breast cancer patients by immunohistochemistry and results were correlated with clinico-pathological characteristics. RESULTS: Expression of Runx2 and ER was reciprocal in the breast cell culture models and Runx2 suppressed ERbeta but not ERalpha mRNA levels. In contrast, functional expression of Runx2 was evident in the nucleus in 28% of the breast cancer tissues and in both early and late stages of tumour growth. Importantly, Runx2 expression was significantly more frequent in Grade 2 compared to Grade 1 and Grade 3 tumours (48% versus 39% versus 13%) and the expression was significantly associated with ER (p=0.005), PR (p=0.008) expressions in Grade 2 & Grade 3 tumours than Grade 1 tumours. CONCLUSION: We propose that Runx2, ER and PR triple positivity in Grades 2 and 3 defines a biological subtype in breast cancer.
PURPOSE: The runt-related transcription factor, Runx2 may have an oncogenic role in mediating metastatic events in breast cancer, but whether Runx2 has a role in the early phases of breast cancer development is not clear. We examined the expression of Runx2 and its relationship with oestrogen receptor (ER) and progesterone receptor (PR) in breast cancer cell lines and tissues. METHODS: Two humanbreast cancer cell lines, MCF-7 and MDA-MB-231 were transiently transfected with vectors expressing either Runx2 or ER and the levels of both proteins and mRNA were examined by Western blot analysis and quantitative real-time PCR, respectively. Runx2 expression was also examined in tissue microarray sections of 123 breast cancerpatients by immunohistochemistry and results were correlated with clinico-pathological characteristics. RESULTS: Expression of Runx2 and ER was reciprocal in the breast cell culture models and Runx2 suppressed ERbeta but not ERalpha mRNA levels. In contrast, functional expression of Runx2 was evident in the nucleus in 28% of the breast cancer tissues and in both early and late stages of tumour growth. Importantly, Runx2 expression was significantly more frequent in Grade 2 compared to Grade 1 and Grade 3 tumours (48% versus 39% versus 13%) and the expression was significantly associated with ER (p=0.005), PR (p=0.008) expressions in Grade 2 & Grade 3 tumours than Grade 1 tumours. CONCLUSION: We propose that Runx2, ER and PR triple positivity in Grades 2 and 3 defines a biological subtype in breast cancer.
Authors: Omar Khalid; Sanjeev K Baniwal; Daniel J Purcell; Nathalie Leclerc; Yankel Gabet; Michael R Stallcup; Gerhard A Coetzee; Baruch Frenkel Journal: Endocrinology Date: 2008-08-28 Impact factor: 4.736
Authors: Hicham Drissi; Arlyssa Pouliot; Christian Koolloos; Janet L Stein; Jane B Lian; Gary S Stein; André J van Wijnen Journal: Exp Cell Res Date: 2002-04-01 Impact factor: 3.905
Authors: A Taranta; M Brama; A Teti; V De luca; R Scandurra; G Spera; D Agnusdei; J D Termine; S Migliaccio Journal: Bone Date: 2002-02 Impact factor: 4.398
Authors: Victoria Wargon; Marina Riggio; Sebastián Giulianelli; Gonzalo R Sequeira; Paola Rojas; María May; María L Polo; María A Gorostiaga; Britta Jacobsen; Alfredo Molinolo; Virginia Novaro; Claudia Lanari Journal: Int J Cancer Date: 2014-11-12 Impact factor: 7.396
Authors: Nyam-Osor Chimge; Sanjeev K Baniwal; Jingqin Luo; Simon Coetzee; Omar Khalid; Benjamin P Berman; Debu Tripathy; Matthew J Ellis; Baruch Frenkel Journal: Clin Cancer Res Date: 2011-12-06 Impact factor: 12.531
Authors: Hanna Taipaleenmäki; Gillian Browne; Jacqueline Akech; Jozef Zustin; Andre J van Wijnen; Janet L Stein; Eric Hesse; Gary S Stein; Jane B Lian Journal: Cancer Res Date: 2015-01-29 Impact factor: 12.701
Authors: Pramod S Gowda; Benjamin J Wildman; Timothy N Trotter; Xiaoxuan Xu; Xiaoxiao Hao; Mohammad Q Hassan; Yang Yang Journal: Mol Cancer Res Date: 2018-03-28 Impact factor: 5.852
Authors: Sandhya Pande; Gillian Browne; Srivatsan Padmanabhan; Sayyed K Zaidi; Jane B Lian; Andre J van Wijnen; Janet L Stein; Gary S Stein Journal: J Cell Physiol Date: 2013-08 Impact factor: 6.384